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Summary The relationship between ploidy, as measured by flow cytometry, and the presence of oestrogen
and progesterone receptors was investigated in 145 primary invasive breast cancers. The tumours were
considered as an integral group, and as subgroups of lobular and ductal carcinomas. An association was
found between the presence of aneuploid stemlines and an absence of oestrogen receptors (ER), for the total
tumour population (P<0.02), and for the ductal carcinoma group (P<0.05). An association between
aneuploidy and an absence of progesterone receptors (PR) was observed for the total tumour group
(P<0.05). Evaluation of a combined oestrogen and progesterone receptor status indicated that the association
between aneuploidy and an absence of both receptors was highly significant. The probability of such an
association was P<0.001 for the total tumour population, and P<0.01 for the ductal tumour group.
Assessment of progesterone receptor expression by breast cancers containing oestrogen receptors indicated
that aneuploid tumours were as likely to express PR as were diploid tumours. Hence, the biological activity of
oestrogen receptors appears unmodified by the presence of aneuploid nuclei.
The presence of oestrogen receptors (ER) in normal
target tissues such as breast or uterine epithelium is
generally accepted as a marker for oestrogenic
regulation of their growth and activity. Likewise,
the presence of oestrogen receptors in malignant
mammary tissue is believed to indicate the potential
oestrogenic regulation of the cancer. Although cyto-
solic oestrogen receptors are used as a guide to the
selection of those patients with advanced disease
who might benefit from endocrine manipulative
therapy, their presence is associated with a reponse
to endocrine therapy in only 50-60% of patients
(Hawkins et al., 1980). In an effort to explain this,
and perhaps also improve selection of these
patients, the association between oestrogen
receptors and a variety of other biological para-
meters has been investigated, e.g. cell cycle kinetics
(Meyer et al., 1984), histological tumour typing and
grading (Howat et al., 1983; Mossler et al., 1980;
Underwood, 1983) and nuclear ploidy. In general,
these studies have shown that variables associated
with poor prognosis in breast cancer appear to be
associated more frequently with an absence of
oestrogen receptors. While the presence of
aneuploid tumour nuclei has been linked to poor
prognosis (Atkin, 1972; Auer et al., 1984), an
association with oestrogen receptor content has not
been conclusively established (Auer et al., 1980;
Bichel, et al., 1982; Cornelisse et al., 1984; Kute et
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al., 1981; Olszewski et al., 1981; Raber et al., 1982;
Taylor et al., 1983). One of these studies (Bichel et
al., 1982) suggested that aneuploidy might be
responsible for the lack of endocrine responsiveness
which occurs in 40% of ER positive tumours.
In this study we have examined the relationship
between the presence of aneuploid nuclei and
oestrogen receptors in a large group of primary
invasive breast cancers. This relationship was
examined for both the entire tumour population
and the ductal carcinomas. In addition, using the
presence of progesterone receptors (PR) as a
marker for an intact oestrogenic regulatory path-
way, we have assessed the likelihood of aneuploidy
having a role in abrogating the biological activity
of oestrogen receptors.
Materials and methods
Chemicals
[2,4,6,7-3H]Oestradiol-17# (SA>85 Ci mmol-1)
was obtained from Amersham Australia Pty. Ltd.,
Sydney, NSW. Both [3H]R5020 (promegestone)
(SA>80 Ci mmol-1) and unlabelled R5020 were
obtained from NEN-Dupont, North Ryde, NSW,
Australia. Diethylstilboestrol, RNase, and ethidium
bromide were obtained from Sigma Chemical Co.,
St Louis, Mo., USA. Triton X100 was obtained
from Ajax Chemicals, Auburn, NSW, Australia.
RPMI 1640 medium was obtained from Gibco,
Grand Island, NY, USA.
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Biopsy specimens
Biopsies from 101 primary invasive breast cancers
were obtained from the Flinders Medical Centre.
Specimens were received in the laboratory, on ice,
within 30min of excision. Biopsy tissue from the
Histopathology Departments of the Queen
Elizabeth Hospital and the Lyell McEwin Hospital
(44 specimens) were delivered frozen on dry ice,
usually within 48h of surgery. All specimens were
stored for 12-48h at -76°C prior to receptor
analysis.
Tumours were subdivided according to patho-
logical type (Table I). For ductal carcinoma, only
those exhibiting homogeneous, specific histopatho-
logical forms were classified as specific variant
types. All other ductal tumours were classified as
ductal carcinoma of no special type (NOS).
Preparation of tumour cytosolfractions
Tumour tissue was homogenised (ultraturrax) in
ice-cold buffer containing 10mm Tris, 1.5mM
EDTA, 1 mm dithiothreitol, 10% glycerol and
20mm sodium molybdate, pH 7.4. The final cytosol
fractions were obtained by centrifugation of the
homogenates at 105,000g for 1 h at 4°C.
Hormone receptor determination
Receptor levels for oestrogen and progesterone
were measured using saturation analysis assays.
Five incubation concentrations, ranging from 0.05
to 2.0 nm for [3H]oestradiol and from 0.08 to 8.0nm
for [3H]R5020, were used to determine total ER
and PR binding, respectively, to the tumour cytosol
fraction. Parallel series of incubations containing
the radioligands in the presence of a 100-fold excess
of appropriate unlabelled ligand (diethylstilboestrol
for [3H]oestradiol and R5020 for [3H]R5020) were
used to estimate the levels of nonspecific binding.
Incubations were conducted in duplicate, in
microtitre plates, with a final incubation volume of
100pl. Following a 16h incubation at 4°C, bound
and free hormone were separated by the addition of
dextran-coated charcoal. Binding data was analysed
according to the method of Scatchard, with least
squares linear regression analysis (Tilley et al.,
1980). Receptor concentrations were expressed as
fmol mg 1 cytosol protein. Tumour cytosols with a
receptor concentration equal to or greater than
10fmol mg-1 protein were graded as positive in this
study. This cut-off was applied to both oestrogen
and progesterone receptor concentrations.
DNA analysis ofbiopsy cell nuclei
Tumour biopsy specimens were sliced in ice-cold
medium RPMI 1640 into 1-2mm fragments, using
scalpels. The cells which spilled out were then
sieved from the residual fragments through 250,im
stainless steel mesh, centrifuged and resuspended to
2 x l06ml-1 in RPMI plus I mgml -1 RNase. A
biological internal standard (chicken RBC) was
used to control both instrument and staining
variability during flow cytometry. The marker
chicken RBC were added to the tumour cell
suspension to a final concentration of
1.5 x 105ml-1. Cell nuclei were then prepared and
stained, by the addition of a half-volume aliquot of
ethidium bromide (0.3mgml-1) in 0.8% (v/v)
Triton X100 (Taylor & Milthorpe, 1980). After
mixing, the nuclei were allowed to remain at room
temperature for 5min, and then sieved through
50pm mesh. DNA analysis was carried out using a
Becton Dickinson FACS IV flow cytometer with
Table I Distribution of histological type, ploidy and hormone receptors
Tmour Aneuploid tumours ER+ tumours PR+ tumours
Histological group n n n n
All tumours 145 83 (57%) 102 (70%) 93 (64%)
Infiltrating lobular 9 2 (22%) 7 (78%) 6 (67%)
Infiltrating ductal 122 74 (61%) 86 (70%) 80 (66%)
no special type (NOS)
Infiltrating ductal
specific variants:
Colloid 4 0 (0%) 4 (100%) 2 (50%)
Tubular 3 0 (0%) 3 (100%) 3 (100%)
Medullary 7 7 (100%) 2 (29%) 2 (29%)
Receptor positive was defined as .10fmolmg' cytosol protein; determined by Scatchard
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laser excitation at 514nm and 500mW. DNA-
specific fluorescence emission was measured using a
580 nm long-pass interference filter. A second
detector, with similar emission filter, was used for
gating out of non-fluorescent particles. The flow
cytometer was calibrated using a mixture of stained
chicken RBC and human peripheral blood lympho-
cytes. The ratio of G1 peak channel number for
diploid versus chicken RBC nuclei was 2.77+0.13
(Mean +s.d., n = 100). Usually 25,000 cells were
measured per specimen, at a flow rate of -1000s-1.
Coefficients of variance were in the order of 3-4%.
All tumours contained a population of diploid
cells. The diploid value of this population was
verified on the basis of their DNA ratio with the
included chicken RBC. Tumours that contained
only a diploid stemline were categorised as diploid
tumours. Tumours with a DNA stemline outside
the 95% confidence interval for diploid were
classified as aneuploid. Tetraploid tumours were
thus classified as aneuploid, as per Meyer et al.
(1984). All DNA profiles were analysed and
allocated to the appropriate ploidy group, prior to
retrieval of the hormone receptor results.
Results
The 145 primary invasive breast cancers were
grouped into the pathological types shown in Table
I. Ductal carcinomas accounted for 136 or 94% of
the tumours examined. The specific variant types
accounted for 14 or 10% of the ductal carcinomas,
the remaining 122 or 90% being classified as ductal
carcinoma of no special type (NOS). The NOS
ductal carcinomas were heterogeneous with respect
to nuclear ploidy - 61% of the carcinomas
possessing one or more aneuploid stemlines. The
specific ductal variant types were homogeneous, but
the numbers examined were small. Colloid and
tubular carcinomas displayed only a diploid stem-
line, while all medullary carcinomas had an
aneuploid stemline.
The incidence of oestrogen receptors in the entire
tumour population was 70% (Table I). All colloid
and tubular carcinomas contained ER, while
between 70-80% of ductal NOS and lobular
carcinomas were ER positive. Only 29% of
medullary carcinomas demonstrated the presence of
oestrogen receptors. The distribution of ER and PR
between the diploid and aneuploid tumour groups
were examined independently for the entire
population of tumours, and for the ductal and
lobular carcinoma groups (Table II). Examination
of the total carcinoma group showed a significant
association between the presence of aneuploid
nuclei and the absence of oestrogen receptors
(P<0.02). A similar inverse association existed for
progesterone receptors (P<0.05). A statistically
significant association was also seen between the
presence of aneuploid nuclei and the absence of
oestrogen receptors for the total ductal carcinoma
group (P<0.05), but was not observed for
progesterone receptors. With the lobular
carcinomas, no significant difference in the
distribution of either receptor type could be found.
Separation of the infiltrating ductal carcinomas
into the NOS and specific variant groups (Table
III), demonstrated a statistical association between
aneuploidy and an absence of oestrogen receptors
only for the specific variant group (P=0.025).
Similar associations were investigated for a
combined receptor status. The absence of both
receptors (ER-PR-) was found to be significantly
associated with the presence of aneuploid nuclei in
the entire tumour group (P<0.001), the total infil-
trating ductal and the NOS subgroups (P<0.01),
and the ductal variant subgroup (P<0.05) (Tables
II and III).
Table II Distribution of receptors in diploid and aneuploid breast cancers
hmour ER PR- ER- PR-
Histological group Ploidy n n n n
All tumours diploid 62 12 16 3
aneuploid 83 31 (P<0.02) 36 (P<0.05) 23 (P<0.001)
Total infiltrating ductal diploid 55 11 15 3
aneuploid 81 30 (P<0.05) 34 (NS) 22 (P<0.01)
Infiltrating lobular diploid 7 1 1 0
aneuploid 2 1 (NS) 2 (NS) 1 (NS)
Receptor negative was defined as <10fmolmg-1 cytosol protein; determined by Scatchard plot analysis.
Fisher's Exact Probability Test was used for testing significance in the lobular group, while the Chi-squared Test
was used for the remaining groups. NS=not significantly different at the 5% level.
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Table III Distribution of receptors within ploidy groups ofinfiltrating ductal carcinomas
Thmour ER PR- ER- PR-
Histological group Ploidy n n n n
Infiltrating ductal diploid 48 11 13 3
no special type aneuploid 74 25 (NS) 29 (NS) 18 (P<0.01)
(NOS)
Infiltrating ductal diploid 7 0 2 0
specific variants aneuploid 7 5 (P=0.025) 5 (NS) 4 (P=0.05)
Receptor negative was defined as <10fmolmg- 1 cytosol protein; determined by Scatchard plot analysis.
Fisher's Exact Probability Test was used for testing significance in the specific variant group, while the Chi-
squared Test was used for the NOS ductal carcinomas. NS=not significantly different at the 5% level.
Distribution ofthe progesterone binding activity of
ER positive tumours
Progesterone receptors were expressed by 74.5% of
all ER positive tumours. When the distribution of
progesterone receptors between diploid and
aneuploid tumours was examined (Table IV), no
significant differences were seen for either the whole
tumour population or for each histological subclass.
Discussion
The proportion of aneuploid tumours in this study
(57%) is in agreement with previously published
values for primary breast cancer (for review, see
Meyer et al., 1984). Similarly, the incidence of ER in
the overall tumour population (70%) is in
agreement with the generally accepted value
(Hawkins et al., 1980). The incidence of ER in the
individual histological types also compare
favourably with those reviewed by Underwood
(1983). Variations in reported incidences of aneu-
ploidy and hormone receptors for primary breast
cancer may be due to intra-tumour heterogeneity.
Analysis of a small fragment of tumour in isolation
might not yield a representative determination. This
problem has been addressed for both hormone
receptor content (Tilley et al., 1978) and ploidy
determination (Thornthwaite et al., 1980), and is
usually overcome as in this study by analysis of
several fragments of tumour obtained from various
sites in the biopsy. Certain tissue dissociation
methods may also result in cell suspensions
qualitatively unrepresentative of the original biopsy
composition. For example, we have observed
similar results to those of Chassevent et al. (1984),
where enzymatic dissociation appeared to selectively
reduce the aneuploid cell populations in the
resulting cell suspension (manuscript in prepara-
tion). Consequently enzymatic dispersion of solid
tumours was not used in this study.
The presence of aneuploid nuclei and oestrogen
receptors appear to be opposing prognostic
indicators in relation to disease course and survival
prospects in breast cancer (Atkin, 1972; Auer et al.,
1984; Hawkins et al., 1980). A statistically
significant association between the presence of
aneuploid tumour nuclei and the absence of ER is
apparent from some studies (Auer et al., 1980;
Table IV Distributions of PR in ER positive breast tumours
ER+ PR+
Histological group Ploidy n n
All tumours diploid 50 37
aneuploid 52 39 (NS)
Total infiltrating ductal diploid 44 32
aneuploid 51 39 (NS)
Infiltrating ductal diploid 37 27
no special type (NOS) aneuploid 49 38 (NS)
Receptor positive was defined as .10fmolmg-1 cytosol protein;
determined by Scatchard plot analysis. Chi-squared was used for
testing significance. NS =not significantly different at the 5% level.STEROID RECEPTORS AND PLOIDY IN BREAST CANCER
Bichel et al., 1982; Olszewski et al., 1981), but in
others only a trend was observed (Cornelisse et al.,
1984; Kute et al., 1981; Raber et al., 1982; Taylor et
al., 1983). We were thus prompted to re-examine
this association. Our results confirm that an
association between the presence of aneuploidy and
the absence of oestrogen receptors does exist as
reported. A statistically significant association was
observed for the entire population of tumours, the
total ductal carcinoma group, and for the specific
ductal variant group. Trends towards a similar
association were seen for the ductal NOS tumours
and for the lobular carcinomas, but statistical
significance was not reached in either case. The low
number of tumours was possibly a contributing
factor for the lobular carcinoma group.
Little has been reported on the association
between aneuploidy and the existence of
progesterone receptors. Meyer et al. (1984) noted a
tendency for diploid carcinomas to be PR positive
more frequently than aneuploid carcinomas, but
statistical significance was not reached. Kute et al.
(1981), using small numbers of mixed primary and
metastatic patients, was also unable to demonstrate
any statistical difference. In this study a statistically
significant association was shown to exist between
aneuploidy and the absence of progesterone
receptors for the total tumour population.
Combination of the receptor markers reinforces
the associations seen between aneuploidy and
oestrogen and progesterone receptors, with the
result that the likelihood of tumours devoid of both
oestrogen and progesterone receptors being
aneuploid is extremely high (P<0.001). The
analysis of combined receptor status revealed data
(Tables II and III) which could be construed to
indicate that a disproportionate number of ER-
tumours expressed progesterone receptors. For
example, it can be calculated from Table II that
40% (17/43) of the ER- tumours expressed PR.
Closer examination however, revealed that 15/17
tumours in this ER-PR' category were derived
from premenopausal patients, which would most
likely explain the high incidence of PR observed in
the absence of measurable levels of ER. A reduced
incidence of detectable oestrogen receptor activity
and a lower receptor concentration have been
generally observed in breast cancers in pre-
menopausal women (for review, see Hawkins et al.,
1980). The presence of both oestrogen and pro-
gesterone receptors is a useful clinical index of
patient response to endocrine therapy. In this
study we have shown that the converse (i.e. the
absence of both receptors) is strongly associated
with the presence of aneuploid nuclei. In the past,
aneuploid nuclei and the absence of hormone
receptors have been considered to be independent
indicators of poor prognosis, but this study
indicates that a strong association exists between
these parameters.
The existence of a population of ER positive
tumours with aneuploid nuclei prompted Bichel et
al. (1982) to suggest that this population might
correspond to those ER positive tumours which do
not respond to endocrine therapy. This study
indirectly examined that proposal by using the
expression of progesterone receptors as a marker of
an intact oestrogenic regulatory system.
Progesterone receptors have been shown to be
regulated by oestrogen in both uterine tissues
(Janne et al., 1975; Kassis et al., 1984) and breast
cancer cell lines (Horwitz & McGuire, 1978). In this
study progesterone receptors were found in 75% of
ER positive tumours with no statistical difference in
the distribution between diploid and aneuploid
tumours. Therefore, we conclude that aneuploidy
appears unlikely to alter the biological activity of
oestrogen receptors. A speculative interpretation of
this data is that the initial response rate to
endocrine therapy might be expected to be similar
in patients with diploid or aneuploid ER positive
breast cancer. Evaluation of the influence of
aneuploidy on the ultimate outcome of hormonal
therapy for ER positive breast cancers is currently
in progress in our laboratory.
In conclusion, this study has demonstrated
statistically significant associations between the
presence of aneuploid nuclei in breast cancer and
the absence of cytosolic oestrogen and progesterone
receptors. However, the similarity in distribution of
progesterone receptor binding activity in diploid
and aneuploid ER positive tumours observed in the
present study suggests that the variable response of
ER positive tumours to endocrine therapy is
attributable to factors other than aneuploidy.
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